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Abstract 
Prion diseases is a group of fatal neurodegenerative diseases which cause serious damages in human and animals. 
Prion diseases-associated isoform (PrPSc), the only marker of these diseases, is abundant in brain only at the late 
stage which makes the disease diagnostic at the presymptomatic stage difficult. Aptamers owing to their intrinsic 
advantages such as excellent stability, easy manipulation and reproducible, nontoxic and diagnostic potential, have 
been applied in protein detection, molecular recognition, cancer diagnostic and cell imaging. Recent years, various 
aptamers that bind to prion protein (PrP) with high affinity and selectivity were selected by different groups and the 
application of aptamers to prion diseases diagnostic is arousing more and more attentions as the intrinsic advantages 
of aptamers. In this context, we will introduce prion diseases, the challenges of prion diseases diagnostic at the 
presymptomatic stage and aptamers against PrP, and then summarize the latest progress of aptamers-based assay for 
prion diseases diagnostic. 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of [name organizer] 
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1. Introduction 
1.1. Prion diseases 
Prion diseases, a group of fatal neurodegenerative diseases, were firstly found in sheep and gradually 
found in other species. Prion diseases include Kuru, Gerstmann-straussier-scheinker disease (GSSD), 
Creutzfeldt-Jakob disease (CJD), Fatal familiar insomnia (FFI) and viriant Creutzfeldtl-Jakob disease 
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(vCJD) in human, Scrapie, Transmissible mink encephalopathy (TME), Bovine spongiform 
encephalopathy (BSE), Feline spongiform encephalopathy (FSE), Chronic wasting disease (CWD) in 
animal [1]. The hallmark of these diseases is the accumulation of abnormal prion protein (PrPSc) which is 
converted from the cellular prion protein (PrPC) [2]. The emergency of vCJD in 1996, which are found to 
be transmitted from BSE to human, trigger urgent development of methods for prion disease diagnositc at 
the presymptomatic stage so as to prevent the potential epidemic of vCJD in human [3]. 
1.2. The major challenge for prion diseases diagnostic 
The main problem is that PrPSc is abundant in brain only at the late stage of the diseases, thus how to 
sensitively and selectively detect the minute quantity of PrPSc is the main challenge for prion diseases 
diagnostic at the presymptomatic stage. Nowadays, two strategies are adopted to improve the sensitivity 
of prion diseases detection. The first one depends on the specific interaction of PrPSc with its antibodies in 
virtue of different spectroscopic technique such as raman spectroscopy, fluorescence correlation 
spectroscopic and Fourier-transformed infrared spectroscopy (FT-IR) [4-9]. However, the widespread of 
these methods cumbered by the specificity and useless of antibodies, expensive equipments and the need 
of high level skill in interpretation of results. The other interesting alteration to improve the sensitivity of 
prion diagnostic is to increase the minute quantity of PrPSc in samples. For example, sodium 
phosphotungstic acid and plasminogen are used to concentrate PrPSc [10, 11] while protein misfolding 
cyclic amplification (PMCA) and cell infection assay are applied to amplify the minute quantity of PrPSc
[12-13]. Among the methods mentioned above, PMCA is considered to be the most promising one for 
prion diagnostic at the pre-symptomatic stage, however the time required to achieve optimal sensitivity is 
3 weeks at least. 
1.3. Aptamers against prion protein 
Taking the advantage of the known capacity of PrPSc to bind nucleic acids such as RNA and DNA, 
several groups are attempting to identify artificial ligand (aptamer) by in vitro selection in large 
randomized library (see in Table 1). The first aptamer that specifically interact with PrPC but not prion 
diseases-associated isoform in brain homogenate, were selected by Weiss and other RNA aptamers such 
as SAF-93, DP7 and 60-3 were also selected later [14-18]. It is known that DNA aptamer is more suitable 
for diagnostic purpose than RNA aptamer since DNA is more resistant against nucleases, which is 
important in cases of prion diagnostic with brain and tissue homogenate [19]. Two DNA aptamers were 
selected by SELEX now, the first one recognizing human recombinant PrP can also bind to cell cultured- 
and brain-derived PrPC of various species such as cattle, sheep and deer [20]. The binding site of this 
DNA aptamer which locates within 23-90 epitope of PrP is similar to that of many RNA aptamers. To 
avoid the interaction with the N-terminal of PrP, Bibby et al selected the second DNA aptamer [21], 
which appear to be more promising in prion diagnostic since a trivalent pool of aptamers was proved to 
reactive against guanidinium-denatured PrPSc. However, it is pity that the two DNA aptamers only 
recognize PrPC and denatured PrPSc.
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Fig. 1 Schematic presentation of PrPC detection with aptamer-mediated fluorescence assay developed by Xiao et al [2]. 
1.4. Aptamer-based assays for prion protein detection 
Aptamers owing to the intrinsic advantages of excellent stability, readily manipulation and 
reproducibility, non toxic and non-immunogenic have been applied in protein detection, molecular 
recognition, cancer diagnostic and cell imaging [22-25]. However, the application of aptamers, especially 
DNA aptamers, in prion diseases diagnostic is just underway. Xiao et al designed the first aptamer-based 
assay for PrPC detection. In their assay, the core sequence of DNA aptamer was located in the loop, three 
guanine bases were added at 3’-terminal and tetramethyl-6-carboxyrhodamine (TAMRA) was modified at 
5’-terminal, see in figure 1 [2].  In the native state, TAMRA was proximity to guanine bases through the 
base-pair of G-C bases, and thus the fluorescence of TAMRA was quenched. However, when target PrPC
was coexistence with aptamer assay, the specific interaction of aptamer with PrP forced TAMRA away 
from guanine with the results of fluorescence restored. When the concentration of PrPC ranges from 1.1 to 
44.7 Pg/mL, a linear relationship was constructed between the fluorescence intensity and the 
concentration. The selectivity of the aptamer-based fluorescence assay was also examined using other 
proteins.
With the purpose of improving the sensitivity of aptamer-based assays, nanomaterials with exceptional 
electrical, optical or magnetical capability were introduced. For example, Hu et al developed an 
ultrasensitive method for PrP detection by making use of the high fluorescence quality of quantum dots 
and the excellent plasmon resonance properties of gold nanoparticles [26]. They also proved that the 
aptamer-based assay was able to detect PrPC in serum without isolation prior to detection. Multi-walled 
nanotubes with high conductivity were used by Hianik and coworkers to develop a high sensitive and 
selective aptamer-based method for PrPC detection [27]. The basic sequence of DNA aptamer reported in 
Ref. [20] was extended by 16-mer thymidine tail modified at the 3’terminal. The designed DNA aptamer 
is part of loop-like structure, as seen in Fig. 2. When the designed aptamer-based assay was coexistence 
with target PrPC, the changes of oscillation frequency could be observed, and at relatively low PrPC
concentrations frequency decreased rather faster and then saturated for DNA aptamer. The limit of 
detection is 20-50 pM for the aptamer assay developed by Hianik and coworkers. 
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Fig. 2 Schematic representation of the biosensor for PrPC detection which is based on DNA aptamer and  MWNTs  and developed 
by Hianik et al [27].
Fig. 3 Schematic presentation of our dual-aptamer strategy for sensitive discrimination and detection of prion disease-associated
isoform developed by Xiao et al [29].
Compared with single-aptamer configuration that has been adopted in most of protein detection assays, 
the sensitivity and selectivity of protein detection assay could be improved dramatically with the 
employment of dual-aptamer configuration [28]. Taking the advantages of dual-aptamer configuration, 
Xiao et al developed an intelligent dual-aptamer strategy for prion diseases-associated isoform 
discrimination and detection both in buffer solution and serum, see in Fig. 3 [29]. The two aptamers, 
which have distinct binding epitopes on PrP, were firstly modified with magnetic microparticles (MMPs) 
and quantum dots (QDs), forming the probes of MMPs-Apt1 and QDs-Apt2. In the presence of target PrP, 
the two probes coassociated with PrP simultaneously and formed MMPs-Apt1-PrP-Apt2-QDs sandwich 
structure through the specific interaction of aptamers and PrP. Owing to the excellent separation ability of 
MMPs and high fluorescence quality of QDs, the sandwich structures could be separated easily from the 
medium and represented high fluorescence. The discrimination of PrPC and PrPRes (prion diseases-
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associated isoform) was based on the distinct binding affinities of aptamers to denatured-PrPC and -PrPRes,
which was induced by denaturing detergent.  For PrPC, it is sensitive to denaturing detergent and the 
binding epitopes of the two aptamers destroyed, thus the fluorescence of MMPs-Apt1-PrPC-Apt2-QDs 
sandwich structure disappeared after treated with denaturing detergent. On the contrary, PrPRes is resistant 
to denaturing detergent and the epitope of Apt2 become more accessible after treated with denaturing 
detergent, thus the fluorescence of MMPs-Apt1-PrPRes-Apt2-QDs sandwich structure enhanced 
dramatically compared with that of native state PrPRes. The further identifications showed that the present 
dual-aptamer assay developed by Xiao et al could be successfully applied to the detection of PrP in 
0.01% brain homogenate, about 1000-fold lower than that of commonly applied antibody-mediated 
assays, which can detect PrP just in 10% brain homogenate. This is the first addressing that dual-aptamer 
configuration was applied in prion diseases detection and the selectivity is high enough for direct PrP 
detection in serum and brain homogenate without isolation and purification pior to assay. 
Although large progresses have been made in the development of aptamer-based assays for prion 
protein detection, there is still a long way for the application of aptamer-based assay in direct clinical 
prion diseases diagnostic at the presymptomatic stage.  
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